Pro Farma AG
Swiss affiliate of an international pharmaceutical group that researches, develops, manufactures and commercialises prescription and licensed medicines. Focus areas include cardiology, urology (including prostate cancer and benign prostatic enlargement) and psychiatry (schizophrenia). Provides pharmacovigilance services, regulatory disclosures and commercialisation/licensing activities in its territory.
Industries
Nr. of Employees
small (1-50)
Pro Farma AG
Products
Reagila
Antipsychotic for treatment of schizophrenia (active ingredient: cariprazine).
Eligard
Urology product (active ingredient: leuprorelin acetate).
Urorec
Treatment for urological conditions (active ingredient: silodosin).
Urocit
Urinary alkaliniser (active ingredient: potassium citrate).
Urispas
Urinary antispasmodic (active ingredient: flavoxate hydrochloride).
Livazo
Lipid-lowering agent (active ingredient: pitavastatin).
Reagila
Antipsychotic for treatment of schizophrenia (active ingredient: cariprazine).
Eligard
Urology product (active ingredient: leuprorelin acetate).
Urorec
Treatment for urological conditions (active ingredient: silodosin).
Urocit
Urinary alkaliniser (active ingredient: potassium citrate).
Urispas
Urinary antispasmodic (active ingredient: flavoxate hydrochloride).
Livazo
Lipid-lowering agent (active ingredient: pitavastatin).
Services
Receiving and processing adverse‑event and safety reports for marketed products via dedicated email and telephone contacts.
Local commercial management, promotion and licensing/in‑licensing of proprietary and under‑license prescription medicines within the Swiss territory.
Receiving and processing adverse‑event and safety reports for marketed products via dedicated email and telephone contacts.
Local commercial management, promotion and licensing/in‑licensing of proprietary and under‑license prescription medicines within the Swiss territory.
Expertise Areas
- Pharmacovigilance
- Commercialisation and licensing
- Cardiology therapeutics
- Urology therapeutics
Key Technologies
- Pharmacovigilance reporting systems
- Regulatory disclosure and reporting processes
- Clinical product development
- Commercial launch and field-force promotion
News & Updates
Introduction of an atypical antipsychotic for treatment of schizophrenia in adults.
Company renamed Pro Farma AG to Recordati AG, based in Baar.
Merger of local entities to consolidate operations.
Headquarters acquired rights to a metoprolol portfolio for Europe.
Recordati S.p.A. Milano acquired 100% of pro Farma AG based in Baar.
Recordati group reported consolidated revenue, operating income and net income for 2020 (figures provided on international page).
Introduction of an atypical antipsychotic for treatment of schizophrenia in adults.
Company renamed Pro Farma AG to Recordati AG, based in Baar.
Merger of local entities to consolidate operations.
Headquarters acquired rights to a metoprolol portfolio for Europe.
Recordati S.p.A. Milano acquired 100% of pro Farma AG based in Baar.
Recordati group reported consolidated revenue, operating income and net income for 2020 (figures provided on international page).